{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004507","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.196254+00:00","generated_at":"2026-05-23T19:44:47.279599+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rhythm Pharma Phase 3 TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in 120 patients","bullets":["Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.","Regulatory submissions in US and EU planned for Q3 2025; setmelanotide could become first approved therapy for acquired hypothalamic obesity.","Cash and short-term investments expected to fund operations into 2027.","No new safety signals; most common AEs were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, headache.","Secondary endpoints: 83% of patients achieved ≥5% BMI or ≥0.2 BMI Z-score reduction; hunger score improved (p=0.003)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004507","json":"https://secwatch.observer/filing/0001558370-25-004507.json","markdown":"https://secwatch.observer/filing/0001558370-25-004507.md","text":"https://secwatch.observer/filing/0001558370-25-004507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/0001558370-25-004507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:44:47.279599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}